**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a study consisting of 10 patients, five patients (three men and two women) aged 21-52 years were described, who developed cytomegalovirus (CMV) reactivation, *Escherichia coli*urinary tract infection (UTI), oral HSV1 infection, coronavirus influenza, graft-versus-host disease (GVHD) or *Enterococcus* UTI following treatment with alemtuzumab, antithymocyte globulin \[rabbit antithymocyte globulin\], cyclophosphamide, fludarabine, mycophenolate mofetil or sirolimus as conditioning regimen for haploidentical haematopoietic stem cell transplantation (HSCT) or GVHD prophylaxis \[*routes, duration of treatments to reaction onsets and outcomes not stated for all*\].

Patient B from table 1 of the article: A 52-year-old man developed CMV reactivation following treatment with alemtuzumab and cyclophosphamide as conditioning regimen for HSCT. The man, who had vaso-occlusive crises secondary to sickle cell disease, was prescribed HSCT. His past medications included hydroxycarbamide \[hydroxyurea\]. Prior to HSCT, he received conditioning regimen consisting of alemtuzumab (0.03 mg/kg on day --7, 0.1 mg/kg on day --6 and 0.3 mg/kg on days --5 to --3), cyclophosphamide (50 mg/kg on days +3 and +4) and total body irradiation. Following conditioning regimen, he underwent HSCT on day 0. He also received concurrent treatment with phenoxymethylpenicillin \[penicillin V\] and unspecified standard antimicrobial prophylaxis. On day +11, he developed CMV reactivation.

Patient 1 from table 1 of the article: A 38-year-old man developed *Escherichia coli*UTI and CMV reactivation following treatment with antithymocyte globulin, cyclophosphamide and fludarabine as conditioning regimen for HSCT; and cyclophosphamide, mycophenolate mofetil and sirolimus for GVHD prophylaxis. The man, who had vaso-occlusive crisis and acute chest syndrome secondary to sickle cell disease, was prescribed HSCT. His past medications included hydroxycarbamide \[hydroxyurea\]. Prior to HSCT, he received conditioning regimen consisting of antithymocyte globulin (0.5 mg/kg on day --9 and 2 mg/kg on days --8 and --7), cyclophosphamide (14.5 mg/kg on days --6 and --5), fludarabine (30 mg/m^2^ on days --6 to --2) and total body irradiation. Following conditioning regimen, he underwent HSCT on day 0. He received GVHD prophylaxis treatment consisting of IV cyclophosphamide (50 mg/kg on days +3 and +4), oral mycophenolate mofetil (15 mg/kg 3 times daily from days +5 to +35) and sirolimus from day +5, dosed for a target trough of 5−15 ng/mL. He also received concurrent phenoxymethylpenicillin \[penicillin V\] and unspecified standard antimicrobial prophylaxis. Subsequently, he developed *Escherichia coli*UTI. He also developed CMV reactivation on day +19.

Patient 3 from table 1 of the article: A 21-year-old man developed oral HSV1 infection, coronavirus influenza, CMV reactivation and GVHD involving skin, liver and eyes following treatment with antithymocyte globulin, cyclophosphamide and fludarabine as conditioning regimen for HSCT; and cyclophosphamide, mycophenolate mofetil and sirolimus for GVHD prophylaxis. The man, who had vaso-occlusive crises secondary to sickle cell disease, was prescribed HSCT. His past medications included hydroxycarbamide \[hydroxyurea\]. Prior to HSCT, he received conditioning regimen consisting of antithymocyte globulin (0.5 mg/kg on day --9 and 2 mg/kg on days --8 and --7), cyclophosphamide (14.5 mg/kg on days --6 and --5), fludarabine (30 mg/m^2^ on days --6 to --2) and total body irradiation. Following conditioning regimen, he underwent HSCT on day 0. He received GVHD prophylaxis treatment consisting of IV cyclophosphamide (50 mg/kg on days +3 and +4), oral mycophenolate mofetil (15 mg/kg 3 times daily from days +5 to +35) and sirolimus from day +5 dosed for a target trough of 5−15 ng/mL. He also received concurrent phenoxymethylpenicillin \[penicillin V\] and unspecified standard antimicrobial prophylaxis. On day +20, he developed CMV reactivation. He also developed oral HSV1 infection, coronavirus influenza and acute skin (grade II) and liver (grade IV) GVHD. Also, he developed moderate chronic GVHD involving liver and eyes. The man was treated with unspecified steroids along with strict compliance with sirolimus. His eye symptoms and bilirubin levels improved. However, he died unexpectedly on day +407 \[*cause of death not stated*\].

Patient 6 from table 1 of the article: A 27-year-old female developed *Enterococcus* UTI following treatment with antithymocyte globulin, cyclophosphamide and fludarabine as conditioning regimen for HSCT; and cyclophosphamide, mycophenolate mofetil and sirolimus for GVHD prophylaxis. The woman, who had vaso-occlusive crisis and acute chest syndrome secondary to sickle cell disease, was prescribed HSCT. Her past medications included hydroxycarbamide \[hydroxyurea\]. Prior to HSCT, she received conditioning regimen consisting of antithymocyte globulin (0.5 mg/kg on day --9 and 2 mg/kg on days --8 and --7), cyclophosphamide (14.5 mg/kg on days --6 and --5), fludarabine (30 mg/m^2^ on days --6 to --2) and total body irradiation. Following conditioning regimen, she underwent HSCT on day 0. She received GVHD prophylaxis treatment consisting of IV cyclophosphamide (50 mg/kg on days +3 and +4), oral mycophenolate mofetil (15 mg/kg 3 times daily from days +5 to +35) and sirolimus from day +5 dosed for a target trough of 5−15 ng/mL. She also received concurrent phenoxymethylpenicillin \[penicillin V\] and unspecified standard antimicrobial prophylaxis. Subsequently, she developed *Enterococcus* UTI.

Patient 8 from table 1 of the article: A 29-year-old woman developed acute gastrointestinal (GI) GVHD following treatment with antithymocyte globulin, cyclophosphamide and fludarabine as conditioning regimen for HSCT; and cyclophosphamide, mycophenolate mofetil and sirolimus for GVHD prophylaxis. The woman, who had vaso-occlusive crisis and acute chest syndrome secondary to sickle cell disease, was prescribed HSCT. Her past medications included hydroxycarbamide \[hydroxyurea\]. Prior to HSCT, she received conditioning regimen consisting of antithymocyte globulin (0.5 mg/kg on day --9 and 2 mg/kg on days --8 and --7), cyclophosphamide (14.5 mg/kg on days --6 and --5), fludarabine (30 mg/m^2^ on days --6 to --2) and total body irradiation. Following conditioning regimen, she underwent HSCT on day 0. She received GVHD prophylaxis treatment consisting of IV cyclophosphamide (50 mg/kg on days +3 and +4), oral mycophenolate mofetil (15 mg/kg 3 times daily from days +5 to +35) and sirolimus from day +5 dosed for a target trough of 5−15 ng/mL. She also received concurrent phenoxymethylpenicillin \[penicillin V\] and unspecified standard antimicrobial prophylaxis. Subsequently, she developed grade II GI GVHD. The woman was treated with unspecified steroids. Subsequently, her GVHD completely resolved.

**Author comment:** *\"The 2 main reasons that patients reported for declining \[haploidentical haematopoietic stem cell transplantation\] were the risk of \[graft-versus-host disease\] in an \[human leukocyte antigen\]-mismatched \[haploidentical haematopoietic stem cell transplantation\] and the toxicity associated with chemotherapy in the conditioning regimen.\"*
